Blog

Video: The Psychedelics Industry in 2021

Jan 26 • 1 min read

We may have already published our 2021: The Year in Psychedelics Report, but that doesn’t mean we shouldn’t still look back and see how far we’ve come as an industry. The video highlights many of the moments we’ll remember and hope to build upon moving forward.

Mindset Pharma Enters Manufacturing Agreement to Produce Next-Generation Psilocybin Drug Candidate, MSP-1014

Jan 25 • 2 min read

Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has entered into a pharmaceutical manufacturing agreement with a leading contract development and manufacturing organization, for the production of pharmaceutical grade batches…

G2 Acquires Lophos Pharma, a peyote focused psychedelics company

Jan 24 • 2 min read

Greenridez 2.0 Acquisitions Corp. is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma. Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports Lophos Pharma’s belief in Peyote’s potential to treat indications ranging from weight loss…

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp.

Jan 21 • 8 min read

Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II (NASDAQ: SPKB) a publicly traded special purpose acquisition company sponsored by an affiliate of Silver Spike Capital (“Silver Spike”), announced today that they have signed a definitive business combination agreement expected to make Eleusis…

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder Treatment

Jan 20 • 3 min read

BetterLife Pharma Inc. (CSE: BETR OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has received a written response from the U.S. Food and Drug Administration (FDA) to its pre-investigational new drug (pre-IND) application for the treatment…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554